Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: A phase 2 clinical trial

Elias Jabbour, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Nicholas J. Short, Deborah Thomas, Koji Sasaki, Michael Rytting, Nitin Jain, Marina Konopleva, Guillermo Garcia-Manero, Richard Champlin, David Marin, Tapan Kadia, Jorge Cortes, Zeev Estrov, Koichi Takahashi, Yogin Patel, Maria R. Khouri, Jovitta JacobRebecca Garris, Susan O'Brien, Hagop Kantarjian

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Fingerprint Dive into the research topics of 'Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: A phase 2 clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences